Skip to content
Subscriber Only

Gilead Pill Slashes HIV Risk in ‘Breakthrough’ Study

A daily pill helped protect gay and bisexual men from catching HIV in a study, the first to show that a drug used to treat the world’s deadliest virus can also be used to prevent it.

Gilead Sciences Inc.’s Truvada, sold since 2004 to subdue HIV in infected people, cut the risk of contracting the AIDS- causing virus by 44 percent, and reduced new infections as much as 73 percent in those who used it most, according to results published yesterday in the New England Journal of Medicine. The findings may boost annual revenue for Gilead, the world’s largest maker of AIDS treatments, by $1 billion.